Transcript level of nucleostemin in newly diagnosed acute myeloid leukemia patients

被引：6

作者：

You, Yong ^{[1
]}

Li, Xiaoqing ^{[2
]}

Zheng, Jine ^{[2
]}

Wu, Yaohui ^{[1
]}

He, Yanli ^{[2
]}

Du, Wen ^{[2
]}

Zou, Ping ^{[1
]}

Zhang, Min ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Hematol, Wuhan 430022, Hubei Province, Peoples R China

[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Stem Cell Res & Applicat,Inst Hematol, Wuhan 430022, Hubei Province, Peoples R China

来源：

LEUKEMIA RESEARCH | 2013年 / 37卷 / 12期

关键词：

Nucleostemin; Acute myeloid leukemia; Risk stratification; Minimal residual disease; MINIMAL RESIDUAL DISEASE; ACUTE MYELOGENOUS LEUKEMIA; POLYMERASE-CHAIN-REACTION; TUMOR-INITIATING CELLS; GENE-MUTATIONS; NORMAL KARYOTYPE; AML PATIENTS; STEM-CELLS; EXPRESSION; WT1;

D O I：

10.1016/j.leukres.2013.09.023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To clarify the role of nucleostemin (NS) in AML, its transcription levels in bone marrow (BM) samples obtained from 128 newly diagnosed AML patients were analyzed. We determined that the highest NS transcription level was in M1 patients, while the lowest NS transcription level was in M3 patients. NS mRNA expression is positively correlated with blast percentages (%) and CD34, CD117 and CD123 antigen expression in BM samples but is unrelated to the transcription level of WTI. A significant difference in NS expression between poor-risk and better-risk and between poor-risk and intermediate-risk AML patients was found. Our initial data indicated that NS can be used for tracking minimal residual disease (MRD) and is a helpful guide for treatment. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：1636 / 1641

页数：6

共 38 条

[31] High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study [J].

Vergez, Francois ;

Green, Alexa S. ;

Tamburini, Jerome ;

Sarry, Jean-Emmanuel ;

Gaillard, Baptiste ;

Cornillet-Lefebvre, Pascale ;

Pannetier, Melanie ;

Neyret, Aymeric ;

Chapuis, Nicolas ;

Ifrah, Norbert ;

Dreyfus, Francois ;

Manenti, Stephane ;

Demur, Cecile ;

Delabesse, Eric ;

Lacombe, Catherine ;

Mayeux, Patrick ;

Bouscary, Didier ;

Recher, Christian ;

Bardet, Valerie .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (12) :1792-1798

[32] Acute myeloid leukemia stem cells and CD33-targeted immunotherapy [J].

Walter, Roland B. ;

Appelbaum, Frederick R. ;

Estey, Elihu H. ;

Bernstein, Irwin D. .

BLOOD, 2012, 119 (26) :6198-6208

[33] Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients [J].

Wang, LH ;

Lin, D ;

Zhang, XW ;

Chen, S ;

Wang, M ;

Wang, JX .

LEUKEMIA RESEARCH, 2005, 29 (12) :1393-1398

[34] Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia [J].

Weisser, Martin ;

Kern, Wolfgang ;

Schoch, Claudia ;

Tschulik, Claudia ;

Hiddemann, Wolfgang ;

Haferlach, Torsten ;

Schnittger, Susanne .

LEUKEMIA & LYMPHOMA, 2006, 47 (12) :2645-2647

[35] The Origin and Evolution of Mutations in Acute Myeloid Leukemia [J].

Welch, John S. ;

Ley, Timothy J. ;

Link, Daniel C. ;

Miller, Christopher A. ;

Larson, David E. ;

Koboldt, Daniel C. ;

Wartman, Lukas D. ;

Lamprecht, Tamara L. ;

Liu, Fulu ;

Xia, Jun ;

Kandoth, Cyriac ;

Fulton, Robert S. ;

McLellan, Michael D. ;

Dooling, David J. ;

Wallis, John W. ;

Chen, Ken ;

Harris, Christopher C. ;

Schmidt, Heather K. ;

Kalicki-Veizer, Joelle M. ;

Lu, Charles ;

Zhang, Qunyuan ;

Lin, Ling ;

O'Laughlin, Michelle D. ;

McMichael, Joshua F. ;

Delehaunty, Kim D. ;

Fulton, Lucinda A. ;

Magrini, Vincent J. ;

McGrath, Sean D. ;

Demeter, Ryan T. ;

Vickery, Tammi L. ;

Hundal, Jasreet ;

Cook, Lisa L. ;

Swift, Gary W. ;

Reed, Jerry P. ;

Alldredge, Patricia A. ;

Wylie, Todd N. ;

Walker, Jason R. ;

Watson, Mark A. ;

Heath, Sharon E. ;

Shannon, William D. ;

Varghese, Nobish ;

Nagarajan, Rakesh ;

Payton, Jacqueline E. ;

Baty, Jack D. ;

Kulkarni, Shashikant ;

Klco, Jeffery M. ;

Tomasson, Michael H. ;

Westervelt, Peter ;

Walter, Matthew J. ;

Graubert, Timothy A. .

CELL, 2012, 150 (02) :264-278

[36] Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study [J].

Willasch, A. M. ;

Gruhn, B. ;

Coliva, T. ;

Kalinova, M. ;

Schneider, G. ;

Kreyenberg, H. ;

Steinbach, D. ;

Weber, G. ;

Hollink, Ihim ;

Zwaan, C. M. ;

Biondi, A. ;

van der Velden, V. H. J. ;

Reinhardt, D. ;

Cazzaniga, G. ;

Bader, P. ;

Trka, J. .

LEUKEMIA, 2009, 23 (08) :1472-1479

[37] Recent advances in the diagnosis and classification of myeloid neoplasms - comments on the 2008 WHO classification [J].

Yin, C. C. ;

Medeiros, L. J. ;

Bueso-Ramos, C. E. .

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2010, 32 (05) :461-476

[38] Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial [J].

Yin, John A. Liu ;

O'Brien, Michelle A. ;

Hills, Robert K. ;

Daly, Sarah B. ;

Wheatley, Keith ;

Burnett, Alan K. .

BLOOD, 2012, 120 (14) :2826-2835

← 1 2 3 4 →